Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Waterfront Wealth Inc.

Waterfront Wealth Inc. raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 10,075 shares of the medical equipment provider’s stock after buying an additional 200 shares during the quarter. Waterfront Wealth Inc.’s holdings in Zimmer Biomet were worth $1,226,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Zimmer Biomet by 19.0% in the first quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock valued at $2,954,843,000 after acquiring an additional 3,695,510 shares during the period. American Century Companies Inc. raised its stake in shares of Zimmer Biomet by 21.2% during the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after buying an additional 852,186 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Zimmer Biomet by 2.3% during the 1st quarter. Geode Capital Management LLC now owns 4,315,167 shares of the medical equipment provider’s stock worth $556,244,000 after buying an additional 96,028 shares during the last quarter. Morgan Stanley raised its stake in shares of Zimmer Biomet by 80.5% during the 4th quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider’s stock worth $395,560,000 after buying an additional 1,384,068 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of Zimmer Biomet by 4.9% during the 3rd quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock worth $345,690,000 after buying an additional 144,147 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on ZBH shares. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. Evercore ISI lifted their price target on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Truist Financial boosted their target price on shares of Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research note on Friday, February 9th. Finally, StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Trading Down 0.6 %

Shares of NYSE:ZBH traded down $0.77 during trading on Wednesday, reaching $121.30. 1,520,357 shares of the stock were exchanged, compared to its average volume of 1,484,111. The firm has a market cap of $24.92 billion, a price-to-earnings ratio of 24.81, a price-to-earnings-growth ratio of 2.28 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $149.25. The firm’s 50-day moving average price is $126.47 and its 200 day moving average price is $119.10. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.88 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.